Valuation : Rezolute, Inc.

Market Cap 474M 408M 383M 350M 654M 44.83B 659M 4.53B 1.76B 22.91B 1.78B 1.74B 73.79B P/E 2026 *
-6.49x
P/E 2027 * -6.98x
Enterprise Value 474M 408M 383M 350M 654M 44.83B 659M 4.53B 1.76B 22.91B 1.78B 1.74B 73.79B EV / Sales 2026 *
-
EV / Sales 2027 * 206x
Free-Float
89.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Rezolute, Inc.

1 day-0.44%
1 week-8.84%
Current month-3.20%
1 month-7.54%
3 months-0.87%
6 months+46.93%
Current year+92.37%
1 week 4.43
Extreme 4.43
4.74
1 month 4.43
Extreme 4.43
5.64
Current year 1.87
Extreme 1.87
5.64
1 year 1.07
Extreme 1.07
11.46
3 years 0.72
Extreme 0.72
11.46
5 years 0.72
Extreme 0.72
11.46
10 years 0.72
Extreme 0.72
100
Manager TitleAgeSince
Chief Executive Officer 58 30/01/2013
Director of Finance/CFO 52 23/01/2024
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 04/05/2022
Director/Board Member 55 20/11/2019
Chairman 68 10/02/2019
Date Insider Type Main position Quantity % Market Cap. Importance
7/2/26 A Tax

Chief Technology Officer

-3,062 0.0035%
7/2/26 A Tax

Chief Financial Officer

-3,062 0.0035%
7/2/26 A Tax

Chief Executive Officer

-8,004 0.0092%
Change 5-day change 1-year change 3-year change Capi.($)
-0.44%-8.84%-37.29%+210.96% 474M
+0.41%-2.07%+41.26%+95.40% 69.02B
-0.88%+1.03%+43.24%+90.44% 66.32B
+0.04%+4.36%-11.72%+459.54% 27.66B
-0.90%-7.65%+2.45%-15.50% 25.84B
-3.00%-2.90%+39.40%+9.41% 26.54B
+0.05%+1.81%+25.79%-17.57% 20.4B
+3.45%-13.46%+222.69%+389.50% 17.63B
-1.49%-4.88%-0.41%+530.26% 15.15B
+1.03%+7.00%+59.98%+160.03% 14.65B
Average -0.17%-2.12%+38.54%+191.25% 28.37B
Weighted average by Cap. -0.27%-0.85%+41.62%+148.51%

Financials

2026 *2027 *
Net sales - 2.3M 1.98M 1.86M 1.7M 3.18M 218M 3.2M 22.01M 8.57M 111M 8.65M 8.46M 358M
Net income -72.7M -62.55M -58.7M -53.7M -100M -6.87B -101M -694M -270M -3.51B -273M -267M -11.31B -75.12M -64.63M -60.65M -55.49M -104M -7.1B -104M -717M -279M -3.63B -282M -276M -11.69B
Net Debt - -
Logo Rezolute, Inc.
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
68
Date Price Change Volume
03/09/26 $4.540 -0.44% 771,933
02/09/26 $4.560 +1.33% 857,320
01/09/26 $4.500 -4.05% 1,020,714
31/08/26 $4.690 +1.52% 749,090
28/08/26 $4.620 -7.23% 1,084,885
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.540USD
Average target price
7.667USD
Spread / Average Target
+68.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RZLT Stock